Session Details

POH03 Beyond the Surface: Innovations and Cutting-Edge Therapies in Non-Melanoma Skin Cancer

Fri, Jul 17, 7:30 AM - 8:30 AM
Mercury Ballroom
1 CME Available Power Hour
View Map

DESCRIPTION

This session will explore the latest advancements and cutting-edge therapeutic techniques in the diagnosis, prognostication, and treatment of non-melanoma skin cancers. Topics will include chemoprophylaxis and field therapy updates, prognostication and surveillance, developments in imaging and artificial intelligence, and systemic and intralesional therapies. Attendees will gain insights into the clinical application of these techniques and their potential to improve patient outcomes.

LEARNING OBJECTIVES

1.

Examine the latest advancements in diagnostic tools and prognostic markers for non-melanoma skin cancers, and assess how these innovations can improve early detection and individualized treatment plans.

2.

Identify and evaluate the latest advancements in therapeutic techniques for the treatment of non-melanoma skin cancer.

3.

Discuss the future directions and potential applications of emerging technologies in the management and treatment of non-melanoma skin cancers.

SCHEDULE

7:30 AM

Chemoprophylaxis and field therapy updates

Kathryn Shahwan, MD, FAAD

7:42 AM

Prognostication and surveillance

David R. Carr, MD, MPH, FAAD

7:54 AM

Innovations in imaging and artificial intelligence

Erica Lee, MD, FAAD

8:06 AM

Systemic and intralesional therapies

Mary L. Stevenson, MD, FAAD

8:18 AM

Q&A

DIRECTOR

Kathryn Shahwan, MD, FAAD

Kathryn Shahwan, MD, FAAD

The Ohio State University

CO-DIRECTOR

David R. Carr, MD, MPH, FAAD

David R. Carr, MD, MPH, FAAD

The Ohio State University College of Medicine

SPEAKERS

Erica Lee, MD, FAAD

Erica Lee, MD, FAAD

Mary L. Stevenson, MD, FAAD

Mary L. Stevenson, MD, FAAD

DISCLOSURES

David R. Carr, MD, MPH, FAAD

Regeneron – Investigator(No Compensation Received);

Erica Lee, MD, FAAD

UpToDate, Inc. – Other(Patent royalties or other compensation for Intellectual Property Rights);

Kathryn Shahwan, MD, FAAD

No financial relationships exist with ineligible companies.

Mary L. Stevenson, MD, FAAD

No financial relationships exist with ineligible companies.